Steady sales of core pharmaceuticals and related products

「Against the backdrop of continued growth in demand for existing products since the second quarter of the current fiscal year, sales of imported active pharmaceutical ingredients increased substantially, resulting in a significant increase in overall business sales year on year. Sales of in-house manufactured active pharmaceutical ingredients also remained strong, supported by strong sales of a new product launched in the second quarter and existing products.」

「Against a backdrop of expanding demand for existing products, sales of imported active pharmaceutical ingredients grew substantially, resulting in sales above those of the same period of the previous year. This upward trend is also expected to continue for the full year. Sales of active pharmaceutical ingredients manufactured in-house and isotopes also remained solid. For active pharmaceutical ingredients manufactured in-house, the launch of new products contributed to higher sales for the period, in addition to stable demand for existing products.」

「Although the company achieved new deliveries of several imported products, overall sales were below those of the same period of the previous year due to the impact of declining sales of the mainstay active pharmaceutical ingredient used in antiepileptic drugs amid intensifying competition. Sales of active pharmaceutical ingredients manufactured in-house also declined slightly year on year, as delivery dates were postponed following a change in the production schedule of a major customer for a mainstay product. The cost ratio improved for the business as a whole, partly due to the increase in product inventories resulting from the aforementioned delivery postponements. However, gross profit for the business as a whole declined with the decrease in sales. Development expenses also increased due to costs related to the relocation of the development center and higher depreciation and amortization. As a result, revenue in the pharmaceuticals business was ¥1,352.258 million, down ¥172.871 million, or 11.3%, from the previous interim accounting period, while operating profit was ¥166.642 million, down ¥31.845 million, or 16.0%.」

「Sales of active pharmaceutical ingredients and other products manufactured in-house substantially exceeded those of the same period of the previous year, owing to continued strong sales of existing mainstay products and contributions from new products launched in the third quarter. However, sales for the business as a whole declined as the temporary increase in demand for the mainstay active pharmaceutical ingredient used in antiepileptic drugs subsided.」

「Sales of active pharmaceutical ingredients and other products manufactured in-house substantially exceeded those of the same period of the previous year, owing to strong sales of existing mainstay products and the launch of several new products in the second quarter. However, this was insufficient to offset the substantial decline in sales of imported active pharmaceutical ingredients, mainly due to the end of the temporary increase in demand for the mainstay active pharmaceutical ingredient used in antiepileptic drugs, and sales for the business as a whole declined.」

「Demand for the mainstay imported active pharmaceutical ingredient used in antiepileptic drugs temporarily increased, then settled down, and sales were slightly below the same period of the previous year. However, sales for the business as a whole increased as active pharmaceutical ingredients manufactured in-house grew.」

「Sales volumes of imported active pharmaceutical ingredients increased, led by the company's mainstay products used in antiepileptic drugs. In addition, sales value increased substantially as selling prices were revised to reflect higher raw material costs. New processing and contract synthesis projects were also acquired steadily.」

「Sales volumes of imported active pharmaceutical ingredients, including those used in antiepileptic drugs, increased. In addition, the company proceeded to pass higher purchase prices on to selling prices, resulting in a substantial increase in sales compared with the same period of the previous year. Gross profit margin declined due to changes in the sales mix of products and merchandise, but the substantial increase in revenue resulted in higher profit.」

「Sales volumes of imported active pharmaceutical ingredients, including those used in antiepileptic drugs, increased. In addition, the company proceeded to pass higher purchase prices on to selling prices, resulting in a substantial increase in sales compared with the same period of the previous year.」

「Sales of imported active pharmaceutical ingredients increased substantially year on year. In addition to higher sales volumes, the increase was also driven by progress in passing supplier price increases through to selling prices.」

「Sales of imported active pharmaceutical ingredients, including the Company's core product of active pharmaceutical ingredients for antiepileptic drugs, increased substantially. The acquisition of new processing projects and contract synthesis projects also progressed favorably.」

「Sales increased as sales of active pharmaceutical ingredients for antiepileptic drugs, a core product, remained strong, while the acquisition of new processing projects and small-scale synthesis projects also progressed favorably.」

「Sales of active pharmaceutical ingredients for hyperkalemia treatments and antiepileptic drugs, the Company's core products, remained solid. In addition, the acquisition of new processing projects and small-scale synthesis projects progressed ahead of schedule. Meanwhile, demand for radioisotopes, which had increased in the previous fiscal year, returned to normal seasonal levels.」

「Sales of calcium polystyrene sulfonate and sodium valproate, the Company's core products, remained solid. In addition, the acquisition of new processing projects progressed smoothly.」

「Although sales increased through the broader rollout of active pharmaceutical ingredients with an established track record of adoption, sales declined due to lower sales of active pharmaceutical ingredients for anti-allergy drugs such as hay fever treatments as a result of measures against COVID-19, as well as delays in the approval of applications to change raw materials, which pushed back sales of certain active pharmaceutical ingredients.」

「Sales of calcium polystyrene sulfonate, the Company's core product, remained solid and exceeded the level in the same quarter of the previous year during the cumulative third quarter under review. Sales of radioisotopes, which had been strong in the previous fiscal year, moderated during the third quarter accounting period, but sales of other products, including imported active pharmaceutical ingredients, also remained solid. Overall sales for the cumulative third quarter under review were slightly above the level in the same quarter of the previous year.」